NRXS (Neuraxis) Short-Term Debt: $0.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRXS Neuraxis Inc NRXS
42 GF Score
Price $6.26
GF Value $3.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Neuraxis Short-Term Debt?

Neuraxis NRXS -0.32% 42 Short-Term Debt is $0.04 Mil as of Jun. 2026. GuruFocus rates NRXS with a GF Score™ of 42/100 and a GF Value™ of $3.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Neuraxis's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.04 Mil.

Neuraxis's quarterly Short-Term Debt declined from Dec. 2025 ($0.15 Mil) to Mar. 2026 ($0.10 Mil) and declined from Mar. 2026 ($0.10 Mil) to Jun. 2026 ($0.04 Mil).

Neuraxis's annual Short-Term Debt increased from Dec. 2023 ($0.15 Mil) to Dec. 2024 ($0.15 Mil) but then declined from Dec. 2024 ($0.15 Mil) to Dec. 2025 ($0.15 Mil).

Neuraxis Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Neuraxis Short-Term Debt Related Terms

Neuraxis Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Neuraxis's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuraxis Short-Term Debt Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.25 0.49 0.15 0.15 0.15

Neuraxis Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.20 0.15 0.10 0.04
NRXS
42GF Score
Neuraxis Inc NRXS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.04 Mil mean?
Neuraxis (NRXS) has a Short-Term Debt of $0.04 Mil as of Jun. 2026.
Is Neuraxis' Short-Term Debt too high?
Neuraxis' current Short-Term Debt is $0.04 Mil. Overall, Neuraxis has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuraxis' Short-Term Debt compare to CSBR and RLYB?
Neuraxis' Short-Term Debt of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Neuraxis's current Short-Term Debt is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuraxis stock overvalued right now?
Based on GuruFocus' analysis, Neuraxis (NRXS) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.38, compared to a current price of $6.26 — trading 85.2% above its estimated fair value. The current Short-Term Debt is $0.04 Mil. Neuraxis' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Neuraxis (NRXS), the current Short-Term Debt is $0.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuraxis (NRXS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued. The current stock price of $6.26 is trading 85.2% above its estimated GF Value™ of $3.38. GuruFocus considers Neuraxis to be Significantly Overvalued.

Key valuation signals for NRXS:

  • Short-Term Debt: $0.04 Mil
  • GF Value™: $3.38 vs. price of $6.26 (85.2% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuraxis Business Description

Address 11611 North Meridian Street, Suite 330, Carmel, IN, USA, 46032
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
42GF Score

Get the complete analysis for NRXS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.26
Price
$3.38
GF Value